130 related articles for article (PubMed ID: 4644242)
21. The mechanism of activation of the first component of complement by a univalent hapten-IgG antibody complex.
Goers JW; Ziccardi RJ; Schumaker VN; Glovsky MM
J Immunol; 1977 Jun; 118(6):2182-91. PubMed ID: 559020
[No Abstract] [Full Text] [Related]
22. Receptors for immunoglobulin and complement on human alveolar macrophages.
Reynolds HY; Atkinson JP; Newball HH; Frank MM
J Immunol; 1975 Jun; 114(6):1813-9. PubMed ID: 1127229
[TBL] [Abstract][Full Text] [Related]
23. The effect of antibodies to complement components C2, C3 and C5 on the production and action of lymphotoxin.
Gately MK; Mayer MM
J Immunol; 1972 Oct; 109(4):728-34. PubMed ID: 5074329
[No Abstract] [Full Text] [Related]
24. Immunoglobulin receptors on mouse mast cells.
Tigelaar RE; Vaz NM; Ovary Z
J Immunol; 1971 Mar; 106(3):661-72. PubMed ID: 4100688
[No Abstract] [Full Text] [Related]
25. Antigenic relationship between the fourth component of human and guinea pig complement.
Ohanian SH; Borsos T
J Immunol; 1975 Jan; 114(1 Pt 1):161-4. PubMed ID: 46239
[TBL] [Abstract][Full Text] [Related]
26. Studies on the relation between the fifth component of complement and anaphylatoxinogen.
Vogt W; Lufft E; Schmidt G
Eur J Immunol; 1971 Apr; 1(2):141-5. PubMed ID: 4108378
[No Abstract] [Full Text] [Related]
27. Complement receptors on cell membranes. I. Evidence for two complement receptors.
Okada H; Nishioka K
J Immunol; 1973 Nov; 111(5):1444-9. PubMed ID: 4795622
[No Abstract] [Full Text] [Related]
28. Alternate complement pathways.
Osler AG; Sandberg AL
Prog Allergy; 1973; 17(0):51-92. PubMed ID: 4277357
[No Abstract] [Full Text] [Related]
29. Immunochemical quantitation of cell bound C4.
Ohanian SH; Borsos T
J Immunol; 1974 Mar; 112(3):979-86. PubMed ID: 4359786
[No Abstract] [Full Text] [Related]
30. [Homoreactant system and immunobiological properties of products of proteolytic splitting of antigen-antibody complexes].
Kul'berg AIa; Shmeleva NE; Bartova LM
Biull Eksp Biol Med; 1972 Jan; 73(1):74-7. PubMed ID: 5062334
[No Abstract] [Full Text] [Related]
31. Combined detection of human T and B lymphocytes by rosette formation with sheep erythrocytes and zymosan-C3 complexes.
Mendes NF; Miki SS; Peixinho ZF
J Immunol; 1974 Aug; 113(2):531-6. PubMed ID: 4546446
[No Abstract] [Full Text] [Related]
32. A simple rosette assay for demonstration of complement receptor sites using complement-coated zymosan beads.
Huber Ch; Wigzell H
Eur J Immunol; 1976 Jun; 5(6):432-5. PubMed ID: 1086242
[TBL] [Abstract][Full Text] [Related]
33. Platelet injury due to activation of the alternate complement pathway.
Siraganian RP; Sandberg AL; Alexander A; Osler AG
J Immunol; 1973 Feb; 110(2):490-7. PubMed ID: 4119252
[No Abstract] [Full Text] [Related]
34. Receptor sites for antigen-antibody complexes on cells derived from solid tumors: detection by means of antibody sensitized sheep erythrocytes labeled with technetium-99m.
Wood GW; Gillespie GY; Barth RF
J Immunol; 1975 Mar; 114(3):950-7. PubMed ID: 1089728
[TBL] [Abstract][Full Text] [Related]
35. Proceedings: Effect of the complement-derived peptides C3a and C5a (anaphylatoxin) on platelets of different species, in vitro.
Grossklaus C; Damerau B; Vogt W
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R59. PubMed ID: 1143463
[No Abstract] [Full Text] [Related]
36. [The interaction of antibody and complement with model membranes (author's transl)].
Inoue K
Tanpakushitsu Kakusan Koso; 1974 Sep; 19(10):741-54. PubMed ID: 4612613
[No Abstract] [Full Text] [Related]
37. Interaction of human anaphylatoxin C3a with rat mast cells demonstrated by immunofluorescence.
ter Laan B; Molenaar JL; Feltkamp-Vroom TM; Pondman KW
Eur J Immunol; 1974 May; 4(5):393-5. PubMed ID: 4136830
[No Abstract] [Full Text] [Related]
38. Increased susceptibility to infection in sickle cell disease: defects of opsonization and of splenic function.
Johnston RB; Newman SL; Struth AG
Birth Defects Orig Artic Ser; 1975; 11(1):322-7. PubMed ID: 238677
[TBL] [Abstract][Full Text] [Related]
39. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of anaphylactic histamine release by Forssman antiserum. I. Characteristics of the reaction and inhibitor.
Duravetz J; Baumal R; Broder I
Immunology; 1976 Jan; 30(1):89-99. PubMed ID: 55380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
